RECIL 2017 criteria demonstrated similar prognostic value and detected a comparable treatment difference between obinutuzumab- and rituximab-chemotherapy compared with Cheson 2007 and Lugano 2014 criteria in patients with previously untreated advanced-stage follicular lymphoma Meeting Abstract
| Authors: | Kostakoglu, L.; Davies, A.; Herold, M.; Hiddemann, W.; Marcus, R.; Trotman, J.; Knapp, A.; Mattiello, F.; Nielsen, T. G.; Sahin, D.; Ward, C.; Younes, A. |
| Abstract Title: | RECIL 2017 criteria demonstrated similar prognostic value and detected a comparable treatment difference between obinutuzumab- and rituximab-chemotherapy compared with Cheson 2007 and Lugano 2014 criteria in patients with previously untreated advanced-stage follicular lymphoma |
| Meeting Title: | 62nd Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 136 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2020 Dec 5-8 |
| Meeting Location: | Virtual |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2020-11-05 |
| Language: | English |
| ACCESSION: | WOS:000607205605069 |
| DOI: | 10.1182/blood-2020-134784 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 25 -- Source: Wos |
